AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

Fatima bint Mubarak Center addresses long-standing gaps in access to advanced genetic testing and precision oncology in the ...

Four of our panelists discuss their favorite investments in the final installment of our 2025 stock-picking confab.

Explore the key catalysts for the FTSE 100 index in the coming week, including the Bank of England decision and key earnings.

As worries about U.S. tariffs eased following U.S. President Donald Trump's decision to delay levies on Canada and Mexico, investors ...

High-risk and potentially high-reward quantum computing stocks include Rigetti Computing, D-Wave Quantum, and IonQ.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...